Pancreas · 2025
Rate of Decrease in Serum Autotaxin Can Predict Relapse of Type 1 Autoimmune Pancreatitis After Initial Steroid Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Horiuchi Ichitaro, Nakamura Akira, Kuraishi Yasuhiro, Sasaki Nobukazu, Minamisawa Masafumi, Kamakura Masato, Kondo Shohei, Yanagisawa Takumi, Oguchi Takaya, Nakajima Tomoyuki, Uehara Takeshi, Nagaya Tadanobu, Shimamoto Satoshi, Igarashi Koji, Umemura Takeji
Аннотация
OBJECTIVES: There are numerous studies on predicting relapse of autoimmune pancreatitis (AIP). Serum autotaxin (ATX) was recently found to associate with AIP relapse. This study examined the changes in serum IgG4 and ATX levels for predicting relapse in AIP patients.
MATERIALS AND METHODS: Patients with AIP who had received initial steroid therapy were retrospectively enrolled. Serum IgG4 and ATX levels were measured before and after treatment. The rates of decrease (Δ) in serum marker levels were calculated by dividing the difference between before and after steroid therapy by the number of days between them.
RESULTS: The 37 AIP patients analyzed included 26 nonrelapse and 11 relapse patients. The median Δ of serum IgG4 was 5.19 [interquartile range (IQR): 2.65-14.49] in the nonrelapse group and statistically comparable to the 3.07 (IQR: 1.79-4.43) in the relapse group ( P =0.12). The median Δ of serum ATX was 1.32×10 -3 (IQR: 0.23×10 -3 -2.45×10 -3 ) in the nonrelapse group and 0.58×10 -3 (IQR: -1.34×10 -3 -0.91×10 -3 ) in the relapse group, which was a significant difference ( P <0.01). Positive predictive values for relapse was 86.5% when the Δ of IgG4 and the Δ of ATX were combined.
CONCLUSIONS: The combination of IgG4 and ATX decrease rates may help predict relapse in AIP patients after steroid therapy.
MATERIALS AND METHODS: Patients with AIP who had received initial steroid therapy were retrospectively enrolled. Serum IgG4 and ATX levels were measured before and after treatment. The rates of decrease (Δ) in serum marker levels were calculated by dividing the difference between before and after steroid therapy by the number of days between them.
RESULTS: The 37 AIP patients analyzed included 26 nonrelapse and 11 relapse patients. The median Δ of serum IgG4 was 5.19 [interquartile range (IQR): 2.65-14.49] in the nonrelapse group and statistically comparable to the 3.07 (IQR: 1.79-4.43) in the relapse group ( P =0.12). The median Δ of serum ATX was 1.32×10 -3 (IQR: 0.23×10 -3 -2.45×10 -3 ) in the nonrelapse group and 0.58×10 -3 (IQR: -1.34×10 -3 -0.91×10 -3 ) in the relapse group, which was a significant difference ( P <0.01). Positive predictive values for relapse was 86.5% when the Δ of IgG4 and the Δ of ATX were combined.
CONCLUSIONS: The combination of IgG4 and ATX decrease rates may help predict relapse in AIP patients after steroid therapy.